Tumor buster - where will the CAR-T cell therapy 'missile' go?

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor (CAR) T cell therapy, a gene-editing based personalized immunotherapy, effectively targets cancer cells.
• While successful in hematologic malignancies, CAR-T cell therapy shows limited efficacy in solid tumors due to antigen escape, toxicity, and the immunosuppressive tumor microenvironment (TME).

Purpose of the Study:

• To comprehensively review therapeutic targets for CAR-T cell therapy in clinical use and development.
• To summarize clinical trials, applications, research frontiers, and limitations of CAR-T cell therapy across various cancers.
• To explore strategies for addressing suboptimal tumor-associated antigens (TAA) or TAA loss in CAR-T cell therapy.

Main Methods:

• Literature review of clinical trials and research on CAR-T cell therapy for cancer.
• Analysis of therapeutic targets, clinical applications, and limitations in solid tumors and hematologic diseases.
• Exploration of coping strategies for antigen escape and TME challenges.

Main Results:

• Identified key therapeutic targets for CAR-T cell therapy, with varying success in different cancer types.
• Highlighted the critical role of target selection in patient prognosis.
• Detailed the challenges and limitations of CAR-T cell therapy in solid tumors, including antigen escape and TME resistance.

Conclusions:

• CAR-T cell therapy is a significant advancement in cancer immunotherapy, with ongoing research focused on optimizing its application in solid tumors.
• Effective target selection and strategies to overcome tumor resistance are crucial for improving patient outcomes.
• Further research into overcoming TME barriers and addressing antigen loss is essential for expanding CAR-T cell therapy's potential.